Contents
Download PDF
pdf Download XML
96 Views
32 Downloads
Share this article
Research Article | Volume 5 Issue 1 (Jan-June, 2024) | Pages 1 - 7
Multifactorial Infection Risks in Cancer Patients: A Comprehensive Review of Epidemiology, Pathogenesis, and Management Strategies
 ,
 ,
 ,
 ,
 ,
Under a Creative Commons license
Open Access
Received
Jan. 18, 2024
Revised
Feb. 21, 2024
Accepted
May 16, 2024
Published
June 30, 2024
Abstract
Cancer, infections, chemotherapy, radiation therapy, bacterial infections, fungal infections, viral infections, immune deficiencies, antibiotic resistance, infection management.
Keywords
Introduction

Cancer patients are particularly vulnerable to developing severe infections, a major complication that significantly contributes to morbidity and mortality in this population. The primary culprits behind this heightened risk are cytotoxic chemotherapy and radiation treatments, both of which are cornerstone therapies for many malignancies. While these treatments are essential for controlling cancer growth and spread, they simultaneously exert profound immunosuppressive effects. Cytotoxic chemotherapy targets rapidly dividing cells, which includes not only cancer cells but also critical components of the immune system, such as white blood cells. This depletion of white blood cells, especially neutrophils, creates a condition known as neutropenia, drastically reducing the body's ability to fight off infections.1,2

Radiation therapy, particularly when targeted at areas of the body rich in bone marrow or lymphatic tissue, further compromises immune function by damaging cells involved in immune responses. This dual assault on the immune system makes cancer patients highly susceptible to a broad spectrum of infections. Among these, bacterial infections are the most prevalent, accounting for the majority of infection-related complications in cancer patients. The high incidence of bacterial infections can be attributed to factors such as the breakdown of mucosal barriers, invasive medical procedures, and prolonged hospital stays, which increase exposure to nosocomial pathogens.3-5

Fungal infections, though less common than bacterial ones, pose a severe threat due to their high mortality rates and the often insidious nature of their onset. The use of broad-spectrum antibiotics to treat bacterial infections can disrupt normal microbial flora, providing an opportunity for opportunistic fungal pathogens to proliferate. Additionally, fungal spores present in the environment can take advantage of the weakened immune defenses in these patients.6-8

Viral infections, while less frequent, are primarily due to the reactivation of latent viruses such as herpes simplex virus (HSV) and cytomegalovirus (CMV). The immunocompromised state of cancer patients allows these dormant viruses to reactivate, leading to significant clinical complications.9,10

Understanding the patterns and risk factors associated with these infections is crucial for developing effective management strategies. This review aims to elucidate these patterns and risk factors, offering insights into preventive measures and therapeutic approaches that can mitigate the impact of infections on cancer patients. By recognizing the multifaceted nature of infection risks and tailoring management strategies accordingly, healthcare providers can significantly improve the prognosis and quality of life for cancer patients.

Host-Associated Factors Predisposing to Infections11-13

Cancer patients' susceptibility to infections is significantly influenced by a variety of host-associated factors that can independently or synergistically increase the risk of infections, complicating the clinical management of cancer.

Immune Deficiencies

Cancer and its treatments often compromise the immune system. Chemotherapy and radiation target rapidly dividing cells, which include both cancer cells and essential components of the immune system, such as white blood cells. This reduction in immune cell counts, particularly neutrophils, significantly diminishes the body's ability to fight off infections. As a result, cancer patients become highly susceptible to a wide range of pathogens, including bacteria, viruses, and fungi.

Medical Comorbidities

The presence of medical comorbidities further exacerbates the risk of infections in cancer patients. Conditions such as Type II diabetes mellitus are particularly concerning as they increase the risk of various infections, including wound infections, genitourinary infections, and fungal infections like candidiasis and rhino-cerebral mucormycosis. These comorbid conditions are associated with shorter remission periods, reduced median survival times, and higher mortality rates, making infection control even more critical in these patients.

Past Infections

A history of previous infections can predispose cancer patients to recurrent infections. Past infections can weaken the overall immune resilience, leaving the body more vulnerable to new infections. This history creates a cycle where each infection further depletes the immune system, making it harder to recover fully.

Nutritional Status

Nutritional status plays a crucial role in immune function. Malnutrition or poor nutritional status can significantly weaken the immune response, making patients more susceptible to infections. Essential nutrients are vital for maintaining a robust immune system, and deficiencies in these nutrients can impair various aspects of immune function, reducing the body's ability to ward off infections.

Psychological Stress

Chronic psychological stress has been shown to impair immune function. Stress-induced immune suppression can increase susceptibility to infections and potentially exacerbate existing conditions. Cancer patients often experience high levels of stress due to the disease and its treatment, which can further compromise their immune defenses.

Neutropenia

Neutropenia, characterized by an abnormally low count of neutrophils (a type of white blood cell essential for fighting infections), is a significant risk factor for infections in cancer patients. This condition is particularly common after chemotherapy for hematologic malignancies, leading to a greatly increased vulnerability to infections. Neutropenic patients are at high risk for developing severe and sometimes life-threatening infections.

Treatment-Associated Factors

In addition to host-associated factors, several treatment-related factors contribute to the heightened risk of infections in cancer patients. These factors are primarily related to the modalities used in the treatment of cancer, which, while essential for controlling the disease, can introduce significant risks.

Surgery and Radiation

Surgery and radiation therapy, while crucial for treating many cancers, can damage tissues and disrupt normal barriers, creating entry points for pathogens. Surgical wounds are particularly susceptible to infections, especially in immunocompromised patients. Radiation can also damage the skin and mucous membranes, further increasing the risk of infections.

Immunosuppressant Therapies

Immunosuppressant therapies, used to manage certain types of cancer, can further weaken the immune system. These therapies include treatments such as corticosteroids and biologic agents that suppress immune responses, increasing the risk of infections. The suppression of immune function can be profound, leaving patients vulnerable to a wide range of opportunistic infections.

Antimicrobial Use

The use of antimicrobials in cancer patients is a double-edged sword. While necessary for treating infections, the overuse or misuse of antimicrobials can lead to the development of drug-resistant infections. Additionally, broad-spectrum antibiotics can disrupt the normal microbial flora, allowing opportunistic pathogens to proliferate. This disruption can lead to infections that are more difficult to treat and control.

Invasive Procedures

Invasive procedures, such as the insertion of central venous catheters, urinary catheters, and other medical devices, are often necessary in the management of cancer patients. However, these procedures can introduce pathogens into the body, increasing the risk of infections. Invasive devices are common sources of nosocomial (hospital-acquired) infections, which are often caused by drug-resistant organisms. The risk associated with these procedures underscores the need for stringent aseptic techniques and vigilant monitoring.

Understanding the host- and treatment-associated factors that predispose cancer patients to infections is crucial for developing comprehensive strategies to prevent and manage these infections. By addressing these factors through targeted interventions, healthcare providers can significantly improve patient outcomes, enhance the overall quality of life, and reduce the morbidity and mortality associated with infections in cancer patients.

Epidemiology and Types of Infections13-15

Infections in cancer patients are a significant concern due to their high prevalence and impact on treatment outcomes. A study conducted at the National Cancer Institute in the United States reported 887 fever episodes in cancer patients, with 36% attributed to microbiologically documented infections. Among these, bacterial infections were the most common, accounting for 252 cases of bacteremia. Although fungal and viral infections were less frequent, they still posed a significant threat to patient health.

Bacterial Infections

Bacterial infections are the predominant type of infection encountered in cancer patients, frequently leading to severe complications. Recent trends have indicated a shift from gram-positive to gram-negative organisms in bloodstream infections, although this varies by geographical region.

  • Lung Cancer: Pulmonary infections are particularly common in lung cancer patients, complicating 50-70% of cases. These infections are primarily caused by pathogens such as Staphylococcus aureus, Haemophilus influenzae, Streptococcus pneumoniae, Enterobacter spp., and Pseudomonas spp. Postoperative pneumonia and wound infections are significant concerns, especially after pulmonary surgery and thoracic radiation. These infections can lead to severe morbidity and prolong recovery times, underscoring the need for vigilant infection control measures and prompt treatment.

Fungal Infections

Fungal infections, although less common than bacterial infections, pose a severe threat due to their high mortality rates. These infections are particularly challenging to manage in cancer patients due to the immunocompromised state induced by cancer treatments.

  • Invasive Aspergillosis: This condition affects 1-8% of lung cancer patients and primarily presents as pulmonary infections. The most common causative agents are Aspergillus fumigatus and Aspergillus flavus. Invasive aspergillosis is associated with significant mortality, and its management requires timely and aggressive antifungal therapy.

  • Head and Neck Cancers: Patients with head and neck cancers are especially susceptible to oropharyngeal candidiasis due to the effects of radiotherapy and chemotherapy. Candida albicans is the most commonly isolated pathogen, but non-albicans species are also prevalent. The disruption of mucosal barriers and immune suppression in these patients create a conducive environment for fungal infections.

Viral Infections

Viral infections in cancer patients generally result from the reactivation of latent viruses, exacerbated by the immunocompromised state of these patients. Common viral pathogens include herpes simplex virus (HSV) and cytomegalovirus (CMV), which can cause significant morbidity in cancer patients. The management of viral infections involves antiviral therapies and supportive care, tailored to the specific viral etiology and patient condition.

Impact of Infections on Cancer Treatment and Outcomes16-18

Infections in cancer patients can have a profound impact on treatment outcomes and overall prognosis. These infections can delay the initiation of chemotherapy, necessitate dose reductions, and prolong hospital stays. Each of these factors contributes to increased healthcare costs and heightened patient morbidity and mortality. The emergence of multidrug-resistant bacteria further complicates treatment efforts, making it imperative to have a thorough understanding of local epidemiology. This knowledge enables healthcare providers to initiate effective empirical antibiotic treatments promptly, improving patient management and outcomes.

The presence of infections also poses a psychological burden on patients and their families, adding to the overall stress associated with cancer treatment. Comprehensive infection control measures, including prophylactic strategies, timely diagnostics, and appropriate therapeutic interventions, are essential to mitigate the impact of infections on cancer patients. By addressing these challenges through multidisciplinary approaches, healthcare providers can enhance the quality of life and survival rates of cancer patients, ensuring better treatment adherence and outcomes.

Examination of Infection Trends in Cancer Patients

Oral Cancer

Oral cancer is a significant health concern in both developing and developed countries, with approximately 405,000 new cases reported annually. Squamous cell carcinoma (SCC) is the predominant type, heavily influenced by the use of tobacco and alcohol, which act synergistically to elevate the risk. In Asian populations, additional factors such as betel nut and tobacco chewing contribute notably to the incidence of oral cancer. Typically, this malignancy occurs in males after the fifth decade of life and is often associated with metastasis to the lungs and bones.

In a study by Raj et al19, changes in oral fungal flora among patients undergoing radiotherapy for head and neck cancer were examined. The study found that 57.14% of patients developed Candida infections during treatment, with Candida tropicalis and Candida parapsilosis being the most prevalent species. This highlights the increased vulnerability of cancer patients to opportunistic fungal infections during radiotherapy.

Lalla et al20 conducted a comprehensive review of oral fungal infections as a side effect of cancer treatment. They observed a significant increase in the incidence of clinical oral candidiasis during and after therapy, with Candida albicans being the most commonly identified species. This underscores the need for monitoring and managing fungal infections in patients undergoing cancer treatment.

Research by Pan et al21 focused on elderly oral cancer patients, particularly those over 70 years old, identifying higher infection rates with drug-resistant organisms such as Candida glabrata, Candida krusei, and methicillin-resistant Staphylococcus aureus (MRSA). This points to the heightened vulnerability of older cancer patients to opportunistic and drug-resistant infections.

Panghal et al22 analyzed 186 patients with oral squamous cell carcinoma and found prevalent bacterial pathogens including Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa. Fungal pathogens such as Candida albicans and Aspergillus fumigatus were also identified, indicating a broad spectrum of infections complicating the treatment of oral cancer patients.

Lung Cancer

Lung cancer is the most prevalent cancer globally, with approximately 1.35 million cases reported annually. Smoking is the primary risk factor, with a clear dose-response relationship between the number of cigarettes smoked and the risk of developing lung cancer. This association underscores the critical need for smoking cessation programs as a preventive measure against lung cancer.

Thai et al23 highlighted that lung cancer patients are particularly prone to bacterial infections caused by pathogens such as Pseudomonas aeruginosa and Staphylococcus aureus. They also noted the susceptibility of these patients to fungal infections like invasive aspergillosis, which further complicates their clinical management.

Apostolou et al24 identified a diverse range of bacterial and fungal species in lung cancer patients, including Mycoplasma spp., Staphylococcus epidermidis, and Candida spp. Their findings emphasize the complex microbial environment and the necessity for comprehensive infection control measures in managing lung cancer.

Sarihan et al25 observed that gram-negative bacteria were the most commonly isolated pathogens in lung cancer patients, followed by gram-positive bacteria and fungi. This finding highlights the shift in the microbial landscape and the need for tailored antimicrobial therapies.

Akinosoglou et al26 reported that pulmonary infections, bacteremia, and gastrointestinal tract infections are common complications in lung cancer patients. Their research underscores the broad range of infectious complications that can arise, necessitating vigilant monitoring and prompt intervention.

Tang et al27 found a high prevalence of candidemia in cancer patients, particularly those with head and neck cancers. Candida albicans was the most frequently observed pathogen, followed by Candida tropicalis and Candida glabrata. This highlights the importance of early detection and treatment of fungal infections to improve patient outcomes.

Bacteremia and Antibiotic Sensitivity

Prabhash et al28 conducted a detailed study on bloodstream infections in cancer patients, identifying Pseudomonas spp., Staphylococcus aureus, and Acinetobacter spp. as common isolates. The study also highlighted the prevalence of broad-spectrum beta-lactamase-producing Enterobacteriaceae, which poses significant challenges in treating infections due to antibiotic resistance.

Talukdar et al29 reported high sensitivity of Staphylococcus aureus to vancomycin, linezolid, and teicoplanin, which are critical antibiotics for managing resistant bacterial infections. However, they also noted variable sensitivity of gram-negative bacteria to antibiotics, indicating the need for continuous surveillance and appropriate antibiotic stewardship.

A retrospective study by Bhat et al30 identified Klebsiella spp., Pseudomonas spp., and Escherichia coli as common bacterial isolates in cancer patients. The study observed significant antibiotic resistance, emphasizing the necessity for judicious use of antibiotics and the development of new antimicrobial strategies to combat resistant infections effectively.

This examination of infection trends in cancer patients highlights the complex interplay of various factors that contribute to infection risk and underscores the need for integrated approaches in managing these infections to improve patient outcomes and quality of life.

Conclusion:

Infections in cancer patients are complex and multifactorial, driven by an interplay of host-related vulnerabilities, aggressive treatment regimens, and environmental exposures. The incidence and nature of bacterial and fungal infections vary significantly with the type of cancer and the specific therapeutic approaches employed. A thorough understanding of local epidemiological trends and antibiotic resistance patterns is essential for devising effective management strategies to mitigate these risks. Targeted research is imperative to develop innovative prevention and treatment protocols tailored to this high-risk population. By addressing these challenges comprehensively, we can significantly improve patient outcomes, enhance quality of life, and increase survival rates among cancer patients.

References:
  1. Seo SK, Liu C, Dadwal SS. Infectious Disease Complications in Patients with Cancer. Crit Care Clin. 2021 Jan;37(1):69-84. 

  2. American Cancer Society. Why People with Cancer Are at Risk of Infections [Internet]. Available from: https://www.cancer.org/cancer/managing-cancer/side-effects/infections/why-people-with-cancer-are-at-risk.html

  3. Gómez V, Mustapha R, Ng K, Ng T. Radiation therapy and the innate immune response: Clinical implications for immunotherapy approaches. Br J Clin Pharmacol. 2020 Sep;86(9):1726-1735.

  4. Rückert M, Flohr A-S, Hecht M, Gaipl US. Radiotherapy and the immune system: More than just immune suppression. Stem Cells. 2021; 39(9): 1155–1165. 

  5. Boopathi E, Den RB, Thangavel C. Innate Immune System in the Context of Radiation Therapy for Cancer. Cancers (Basel). 2023 Aug 4;15(15):3972.

  6. Boussina A, Ramesh K, Arora H, Ratadiya P, Nemati S. Differentiation of Fungal, Viral, and Bacterial Sepsis using Multimodal Deep Learning. medRxiv [Preprint]. 2023 Apr 11:2023.04.10.23288378. 

  7. The Conversation. Antibiotics can lead to life-threatening fungal infection because of disruption to the gut microbiome: New study [Internet]. Available from: https://theconversation.com/antibiotics-can-lead-to-life-threatening-fungal-infection-because-of-disruption-to-the-gut-microbiome-new-study-182881

  8. Oliveira M, Oliveira D, Lisboa C, Boechat JL, Delgado L. Clinical Manifestations of Human Exposure to Fungi. Journal of Fungi. 2023; 9(3):381.

  9. Boldogh I, Albrecht T, Porter DD. Persistent Viral Infections. In: Baron S, editor. Medical Microbiology. 4th edition. Galveston (TX): University of Texas Medical Branch at Galveston; 1996. Chapter 46. Available from: https://www.ncbi.nlm.nih.gov/books/NBK8538/

  10. Zembower TR. Epidemiology of infections in cancer patients. Cancer Treat Res. 2014;161:43-89.

  11. Safdar A, Bodey G, Armstrong D. Infections in Patients with Cancer: Overview. Principles and Practice of Cancer Infectious Diseases. 2011 Jan 4:3–15. 

  12. Persing DH, Prendergast FG. INFECTION, CANCER, AND THE IMMUNE RESPONSE. In: Institute of Medicine (US) Forum on Microbial Threats; Knobler SL, O'Connor S, Lemon SM, et al., editors. The Infectious Etiology of Chronic Diseases: Defining the Relationship, Enhancing the Research, and Mitigating the Effects: Workshop Summary. Washington (DC): National Academies Press (US); 2004. Available from: https://www.ncbi.nlm.nih.gov/books/NBK83682/

  13. Dropulic LK.Lederman HM. 2016. Overview of Infections in the Immunocompromised Host. Microbiol Spectr 4:10.1128/microbiolspec.dmih2-0026-2016.

  14. Safdar A, Bodey G, Armstrong D. Infections in Patients with Cancer: Overview. Principles and Practice of Cancer Infectious Diseases. 2011 Jan 4:3–15. 

  15. Joudeh, N., Sawafta, E., Abu Taha, A. et al. Epidemiology and source of infection in cancer patients with febrile neutropenia: an experience from a developing country. BMC Infect Dis 23, 106 (2023). 

  16. Kubeček O, Paterová P, Novosadová M. Risk Factors for Infections, Antibiotic Therapy, and Its Impact on Cancer Therapy Outcomes for Patients with Solid Tumors. Life (Basel). 2021 Dec 11;11(12):1387.

  17. National Cancer Institute. Infection [Internet]. Available from: https://www.cancer.gov/about-cancer/treatment/side-effects/infection

  18. Centers for Disease Control and Prevention. Preventing Infections in Cancer Patients [Internet]. Available from: https://www.cdc.gov/cancer/features/preventing-infections.html

  19. Raj S, Sharma D, Mate P, Capoor MR, Bhowmik KT. A study of changes in the oral fungal flora of patients on radiotherapy for head and neck malignancies and their correlation with funguria and fungemia. Indian Journal of Cancer. 2017 Jan 1;54(1):39-42.

  20. Lalla RV, Latortue MC, Hong CH, Ariyawardana A, D’Amato-Palumbo S, Fischer DJ, Martof A, Nicolatou-Galitis O, Patton LL, Elting LS, Spijkervet FK. A systematic review of oral fungal infections in patients receiving cancer therapy. Supportive Care in Cancer. 2010 Aug; 18:985-92.

  21. Pan J, Zhao J, Jiang N. Oral cavity infection: an adverse effect after the treatment of oral cancer in aged individuals. Journal of Applied Oral Science. 2014 Jul; 22:261-7.

  22. Panghal M, Kaushal V, Kadayan S, Yadav JP. Incidence and risk factors for infection in oral cancer patients undergoing different treatments protocols. BMC Oral Health. 2012 Dec;12(1):1-2.

  23. Thai AA, Solomon BJ, Sequist LV, Gainor JF, Heist RS. Seminar lung cancer. Lancet. 2021; 398:535-54.

  24. Apostolou P, Tsantsaridou A, Papasotiriou I, Toloudi M, Chatziioannou M, Giamouzis G. Bacterial and fungal microflora in surgically removed lung cancer samples. Journal of cardiothoracic surgery. 2011 Dec; 6:1-5.

  25. Sarihan S, Ercan I, Saran A, Çetintas SK, Akalin H, Engin K. Evaluation of infections in non-small cell lung cancer patients treated with radiotherapy. Cancer detection and prevention. 2005 Jan 1;29(2):181-8.

  26. Akinosoglou KS, Karkoulias K, Marangos M. Infectious complications in patients with lung cancer. Eur Rev Med Pharmacol Sci. 2013;17(1):8–18.

  27. Tang HJ, Liu WL, Lin HL, Lai CC. Epidemiology, and prognostic factors of candidemia in cancer patients. PLoS One. 2014 Jun 5;9(6): e99103.

  28. Prabhash K, Medhekar A, Ghadyalpatil N, Noronha V, Biswas S, Kurkure P, Nair R KR. Blood stream infections in cancer patients: a single center experience of isolates and sensitivity pattern. Indian journal of cancer. 2010 Apr 1;47(2).

  29. Talukdar A, Barman R, Sarma A, Sharma JD, Krishnatreya M, Hazarika M, Kataki AC. Bacteriological profile and antibiotic sensitivity pattern of clinical isolates in a tertiary cancer care center in the Northeast India. South Asian Journal of Cancer. 2020 Jun;9(02):115-9.

  30. Bhat S, Muthunatarajan S, Mulki SS, ArchanaBhat K, Kotian KH. Bacterial infection among cancer patients: Analysis of isolates and antibiotic sensitivity pattern. Int J Microbiol. 2021; 2021:8883700.

Recommended Articles
Research Article
Knowledge about Risk and Preventive factors for Osteoarthritis Knee among Ortho OPD patients in Regional Hospital, Keylong in District Lahaul & Spiti of Himachal Pradesh
Download PDF
Research Article
A Descriptive cross-sectional study to evaluate the Knowledge about Symptoms and Risk Factors for Heart attack (Myocardial Infarction) among the general population of New Delhi
Download PDF
Research Article
A Comparative Study of the Nalbuphine with Fentanyl with Fentanyl as An Adjuvant to Hyperbaric 0.5% Bupivacaine in Spinal Anaesthesia
Download PDF
Research Article
A Randomised Controlled Trial Comparing the Effect of Oral Preemptive Pregabalin Comapred to Iv Lignocaine in Attenuating Hemodynamic Response to Laryngoscopy
Download PDF
Chat on WhatsApp
Flowbite Logo
PO Box 101, Nakuru
Kenya.
Email: office@iarconsortium.org

Editorial Office:
J.L Bhavan, Near Radison Blu Hotel,
Jalukbari, Guwahati-India
Useful Links
Order Hard Copy
Privacy policy
Terms and Conditions
Refund Policy
Shipping Policy
Others
About Us
Contact Us
Online Payments
Join as Editor
Join as Reviewer
Subscribe to our Newsletter
+91 60029-93949
Follow us
MOST SEARCHED KEYWORDS
Copyright © iARCON Internaltional LLP . All Rights Reserved.